Fuji Pharma Co., Ltd.

TSE:4554 Stock Report

Market Cap: JP¥37.7b

Fuji Pharma Future Growth

Future criteria checks 1/6

Fuji Pharma's earnings are forecast to decline at 7.6% per annum while its annual revenue is expected to grow at 5.4% per year. EPS is expected to decline by 7.6% per annum. Return on equity is forecast to be 7.1% in 3 years.

Key information

-7.6%

Earnings growth rate

-7.6%

EPS growth rate

Pharmaceuticals earnings growth11.1%
Revenue growth rate5.4%
Future return on equity7.0%
Analyst coverage

Low

Last updated12 Dec 2024

Recent future growth updates

Recent updates

Fuji Pharma Co., Ltd. (TSE:4554) Held Back By Insufficient Growth Even After Shares Climb 27%

Dec 02
Fuji Pharma Co., Ltd. (TSE:4554) Held Back By Insufficient Growth Even After Shares Climb 27%

Impressive Earnings May Not Tell The Whole Story For Fuji Pharma (TSE:4554)

Nov 20
Impressive Earnings May Not Tell The Whole Story For Fuji Pharma (TSE:4554)

Lacklustre Performance Is Driving Fuji Pharma Co., Ltd.'s (TSE:4554) 27% Price Drop

Aug 05
Lacklustre Performance Is Driving Fuji Pharma Co., Ltd.'s (TSE:4554) 27% Price Drop

Fuji Pharma's (TSE:4554) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 22
Fuji Pharma's (TSE:4554) Shareholders Will Receive A Bigger Dividend Than Last Year

Fuji Pharma (TSE:4554) Is Increasing Its Dividend To ¥22.50

Jul 03
Fuji Pharma (TSE:4554) Is Increasing Its Dividend To ¥22.50

Fuji Pharma (TSE:4554) Has Announced That It Will Be Increasing Its Dividend To ¥22.50

Jun 19
Fuji Pharma (TSE:4554) Has Announced That It Will Be Increasing Its Dividend To ¥22.50

Impressive Earnings May Not Tell The Whole Story For Fuji Pharma (TSE:4554)

May 21
Impressive Earnings May Not Tell The Whole Story For Fuji Pharma (TSE:4554)

Fuji Pharma (TSE:4554) Will Pay A Larger Dividend Than Last Year At ¥22.50

May 13
Fuji Pharma (TSE:4554) Will Pay A Larger Dividend Than Last Year At ¥22.50

Fuji Pharma's (TSE:4554) Dividend Will Be ¥20.00

Feb 28
Fuji Pharma's (TSE:4554) Dividend Will Be ¥20.00

Earnings and Revenue Growth Forecasts

TSE:4554 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202760,0573,7772,7687,7802
9/30/202655,8293,6452,9867,6102
9/30/202550,8003,4702,8237,1802
9/30/202446,1386,146-2214,151N/A
6/30/202444,5626,363N/AN/AN/A
3/31/202443,0525,920-5,278-44N/A
12/31/202341,6395,060N/AN/AN/A
9/30/202340,8893,435-1,9801,917N/A
6/30/202338,4382,036N/AN/AN/A
3/31/202336,9252,634-1,9441,934N/A
12/31/202235,9762,692N/AN/AN/A
9/30/202235,4262,696-13,081-658N/A
6/30/202234,9622,433N/AN/AN/A
3/31/202234,4392,245-11,551512N/A
12/31/202134,1412,222N/AN/AN/A
9/30/202133,9902,4322,0975,993N/A
6/30/202134,3923,161N/AN/AN/A
3/31/202134,1653,7964,9467,733N/A
12/31/202034,1202,668N/AN/AN/A
9/30/202033,7932,0853,1555,770N/A
6/30/202033,8542,006N/AN/AN/A
3/31/202034,7011,5774,4647,196N/A
12/31/201934,9682,611N/AN/AN/A
9/30/201936,2792,9623,7517,035N/A
6/30/201937,3613,287N/AN/AN/A
3/31/201938,4313,3241,2224,352N/A
12/31/201838,2313,167N/AN/AN/A
9/30/201837,9093,3722,1433,773N/A
6/30/201837,2433,219N/AN/AN/A
3/31/201836,0243,255N/A3,489N/A
12/31/201736,4123,525N/AN/AN/A
9/30/201735,3873,301N/A3,238N/A
6/30/201735,2173,141N/AN/AN/A
3/31/201734,7172,835N/A4,138N/A
12/31/201634,2342,650N/AN/AN/A
9/30/201634,2292,118N/A4,509N/A
6/30/201633,7082,354N/AN/AN/A
3/31/201633,0562,293N/A2,257N/A
12/31/201532,5402,121N/AN/AN/A
9/30/201531,6802,092N/A589N/A
6/30/201531,2542,030N/AN/AN/A
3/31/201530,4971,947N/A1,338N/A
12/31/201430,3782,051N/AN/AN/A
9/30/201429,2152,078N/A2,757N/A
6/30/201428,1092,094N/AN/AN/A
3/31/201427,3561,982N/A4,290N/A
12/31/201326,1001,999N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4554's earnings are forecast to decline over the next 3 years (-7.6% per year).

Earnings vs Market: 4554's earnings are forecast to decline over the next 3 years (-7.6% per year).

High Growth Earnings: 4554's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 4554's revenue (5.4% per year) is forecast to grow faster than the JP market (4.2% per year).

High Growth Revenue: 4554's revenue (5.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4554's Return on Equity is forecast to be low in 3 years time (7.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:14
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fuji Pharma Co., Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yoshinaga ToshiakiAizawa Securities Co. Ltd.
Masao YoshidaIchiyoshi Research Institute Inc.
Shigekazu IshidaMarusan Securities Co. Ltd.